DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Back Matter (PDF) INDEX Volume 250, July-September, 1989 Acad, B.-A. and Weiss, H. R: Regional modification of status, obesity (dogs), inhalational, hepatobiliary clearance, 02 consumption and coronary flow 1061 cholephilic xenobiotics (rats), 421 during Beta adrenoceptor stimula- postjunctional, anococcygeus muscle local, induced injury to sciatic nerve, his- tion in reperfused canine myocar- (rats), 492 tologic analysis (rats), 406 dium, 611 beta Angiotensin II Acetaminophen, -induced necrosis, hepato- basal activity, phosphatidic acid phos- -adenosine interactions protective effects, cystathionine phatase (rats), 236 heart rate changes, aldosterone release (rats), 667 02 consumption and coronary flow, (rats), 442 Acetylcholine myocardium (dogs), 611 noradrenergic neurotransmission, a-aminobutyric acid outflow, morphine Adrenocorticotropin, acute and chronic vasoconstriction (rats), 433 withdrawal, alpha receptors (guinea phencyclidine administration (rats), antihypertensive mechanism of captopril, pigs), 682 534 renal hypertension (rats), 515 endogenous release, muscarinic modula- Aging, defective modulation, noradrenergic defective modulation, noradrenergic neu- tion, neostriatal slices (rats), 617 neurotransmission, prostaglandins rotransmission, prostaglandins preclinical studies of quinelorane (rats), (rats), 9 (rats), 9 227 Ahlers, S. T., see Barrett, J. E., 788 minimal receptor domains (rabbits), 31 Acetylcholinesterase Ahiers, S. T., see Gleeson, S., 809 nonpeptide receptor antagonists, struc- changes in drinking activity, electrolyte Albelda, S. M., see Howell, R. E., 93 ture-function studies (rats), 867 excretion, diisopropylfluorophos- Albumin Angus, P. W., Mihaly, G. W., Morgan, D. J. phate (rats), 202 active furosemide fraction, urine compo- and Smallwood, R. A.: Oxygen de- discriminative stimulus effects, physo- sition, nephrotic syndrome, 772 pendence of omeprazole clearance stigmine (rats), 241 methotrexate transport, proximal tubule and sulfone and sulfide metabolite muscarinic receptor subtype regulation, (rabbits), 688 formation in the isolated perfused rat tetrahydroaminoacridine (rats), 573 Albuquerque, E. X., see Alkondon, M., 842 liver, 1043 Adenosine Alcohol, luteinizing hormone releasing hor- Anoxia, pulmonary venule contractions, ar- -angiotension II interactions mone, anterior pituitary and gonadal achidonic acid metabolites (guinea heart rate changes, aldosterone release hormones, women, 902 pigs), 1097 (rats), 442 Aldosterone, release and heart rate changes, Anterior pituitary, gonadal hormones and, noradrenergic neurotransmission, adenosine-angiotensin II interac- luteinizing hormone releasing hor- (rats), 433 vasoconstriction tions (rats), 442 mone, alcohol effects in women, 902 pulmonary vasodilator response, adeno- Alkondon, M. and Albuquerque, E. X.: The Antibiotics, transport of imipenem, central sine 5’-triphosphate, pulmonary vas- nonoxime bispyridinium compound nervous system (rats), 979 cular bed (cats), 170 SAD-128 alters the kinetic properties Anticonvulsants Adenosine triphosphatase of the nicotinic acetyicholine recep- amygdala-kindled rats, valproic acid, 1067 cardiac sarcoplasmic reticulum, calmod- tsr ion channel: A possible mecha- CGS 19755, behavioral pharmacological ulin, free oxygen radicals (dogs), 286 nism for antidonal effects, 842 profile (mice), 454 N-ethylmaleimide sensitivity, vanadate Altszuler, N., see Tuman, R. W., 836 Antidepressants, 5-hydroxytryptamine, re- stimulation, nephron (rats), 529 Amiloride analog, inhibition, bradykinin-in- ceptors, differential-reinforcement- Adenosine triphosphate, -sensitive outward duced cytosolic calcium increase of-low rate 72-sec schedule (rats), 52 potassium current, nicorandil, yen- (dogs), 795 Antihypertensive drugs, nonpeptide angio- tricular myocytes (guinea pigs, rab- 2-Amino-4,5-(1,2-cyclohexyl)-7-phospho- tensin II receptor antagonists, struc- bits), 278 nohaptanoic acid, pharmacological ture-function studies (rats), 867 Adipose tissue, modification of adrenergic profile (rats, mice, gerbils), 100 Antinociception status, obesity (dogs), 1061 Amino acids, NMDA receptor site, compet- infused spinal agents, magnitude of tol- Adrenal cortex, nonpeptide angiotensin II itive inhibitors, guanine nucleotides erance, continuous infusion (rats), 1 receptor antagonists, structure-func- tion studies (rats), 867 (rats), 162 opioid, role, histamine and H,-receptors Adrenoceptors a-Aminobutyric acid, changes in cortical ac- (rats), 476 alpha etylcholine, morphine withdrawal, at- serotonergic involvement, tolerance, U- binding site density and contractile re- pha receptors (guinea pigs), 682 50,488H (mice), 508 sponse, vascular tissues (dogs), 1119 ‘y-Aminobutyric acid, release from electri- Antioxidants, protection, glutamate-in- morphine withdrawal, acetylcholine cally stimulated cortical slices, mod- duced cytotoxicity, neuronal cells and a-aminobutyric acid (guinea ulation, GABAS autoreceptors (rats), (mice), 1132 pigs), 682 648 Antonelli, T., see Beani, L., 682 neuropeptide Y, blood vessel response Amrick, C. L., see Bennett, D. A., 454 Anxiolytics to norepinephrine (rabbits), 523 Amygdala, -kindled rats, valproic acid, 1067 behavioral studies, serotonin receptor reduction of outward currents, ventric- Analgesia subtypes (pigeons), 809 ular myocytes (rats), 364 conditional fear-induced, opioid mu and CGS 19755, behavioral pharmacological alpha-i, 1,4,5-inositol trisphosphate for- kappa receptors (rats), 825 profile (mice), 454 mation, ventricular myocytes (rats), effects of phencyclidine-like drugs (mon- Aorta 1141 keys), 197 cellular mechanisms of endothelin (rats), alpha-2 purine antinociception, adenosine recep- 548 catecholamine receptors and mela- tore, spinal cord (rats), 915 contraction, prostaglandins, protein ki- tonin, retina and pineal gland Anderson, D., see McKinney, M., 565 nasa C mechanism (rats), 44 (chicken), 86 Anesthetics Apomorphine, dopaminergic Dl and D2 ag- 1162 Index Vol. 250 onists, behavioral differentiation, methyl-D-aspartate at its receptor Billings, J., see Schonwetter, B. S., 110 stimulus properties (rats), 800 site both in vitro and in vivo, 162 i,3-Bis(2-chloroethyl)-i-nitrosourea, phe- Arachidonic acid Barone, S., Churchill, P. C. and Jacobson, nytoin teratogenicity, embryonic glu- blockade ofEGF-induced uterine contrac- K. A.: Adenosine receptor prodrugs: tathione reductase (mice), 336 tions, indomethacin, nordihydro- Towards kidney-selective di- Bispyridinium, SAD-128, nicotinic acetyl- guaritic acid (rats), 882 alkylxanthines, 79 choline receptor kinetics (frogs), 842 lipoxygenation, interleukin 1 induction, Barrett, J. E., see Gleeson, S., 809 Bjornsson, T. D., Schneider, D. E. and Ber- prostaglandin biosynthesis (rats), Barrett, J. E., Zhang, L., Ahlers, S. T. and ger, H., Jr.: Asprin acetylates fibrin- 714 Wojnicki, F. H.: Acute and chronic ogen and enhances fibrinolysis. Fi- metabolites, pulmonary venule contrac- effects of corticotropin-releasing fac- brinolytic effect is independent of tions, hypoxia and anoxia (guinea tor on schedule-controlled respond- changes in plasminogen activator pigs), 1097 ing and neurochemistry of pigeons, levels, 154 Arai, Y., see Tadano, T., 254 788 Bladder Arnold, W. S., see Trugman, J. M., 1156 Bazzato, G., see Sabatini, S., 910 membrane, phthalate acid esters, trans- Artery Beani, L., Tanganelli, S., Antonelli, T., Si- port effect (toads), 910 adrenoceptor mechanisms (dogs), 1119 monato, M., Spalluto, P., Tomasini, purine antinociception, adenosine recep- basilar, two populations, 5-hydroxytrypt- C. and Bianchi, C.: Changes in cor- tore, spinal cord (rats), 915 amine receptors (dogs), 379 tical acetylcholine and a-aminobu- 9-Blocking drugs, atenolol, stereoselective blood vessel response to norepinephrine, tyric acid outflow during morphine central hypotensive action (rats), 759 neuropeptide Y, sympathetic field withdrawal involve Alpha-i and Al- Blood flow stimulation (rabbits), 523 pha-2 receptors, 682 models of hepatic elimination, taurocho- coronary, nonneurogenic relaxation, field Beaumont, K., Vaughn, D. A. and Healy, D. late, diazepam (rats), 1048 stimulation (cattle), 461 P.: Thiazide diuretic receptors: Au- regional, endothelin effects (monkeys), generation of endothelium-derived relax- toradiographic localization in rat kid- 1125 ing factor, 5-lipoxygenase products ney with [3Hjmetolazone, 414 Blood pressure (dogs), 1055 Beaune, P., see Labbe, G., 1034 catecholaminergic ventrolateral medul- mesenteric, TA3090 actions, electrical Behavior lary neurons, hypotension correla- and mechanical responses (rabbits), conditional fear-induced analgesia, opioid tion, clonidine (rats), 642 1079 mu and kappa receptors (rats), 825 desoxycorticosterone acetate-sodium hy- prejunctional inhibitory effect of N-0437, differential-reinforcement-of-low-rate pertensive rats, SCH 39370, atrial vascular adrenergic responses (rats), 72-second natriuretic factor, 624 853 5-hydroxytryptamine, receptors (rats), L-glutamate as neurotransmitter, barore- Ascorbic acid, preclinical studies of quinlor- 60 ceptor information, nucleus of trac- ane (rats), 227 5-hydroxytryptamine-2 antagonists tus solitarius (rats), 953 Aspirin, acetylation of fibrinogen and en- (rats), 52 mediation, serotonin receptors, m-chlo- hanced fibrinolysis (humans), 154 role of noradrenaline, anxiogenic actions, rophenylpiperazine (rats), 72 Assays, radioligand binding, characteriza- benzodiazepine receptor agonist rise, cyclosporine, decreased renal vascu- tion of D2 receptors, caudate (dogs), (rats), 358 lar responses
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Proceedings of the British Pharmacological Society Clinical Pharmacology Section
    PROCEEDINGS OF THE BRITISH PHARMACOLOGICAL SOCIETY CLINICAL PHARMACOLOGY SECTION 9-11 September 1987 UNIVERSITY OF OXFORD For oral communications with more than one author, an asterisk(*) denotes the one who presented the work. 90P Proceedings of the BPS, 9-11 September 1987 COMMUNICATIONS Low dose angiotensin II enhances proximal min clearance period (CP). Urine was collected tubular sodium reabsorption in man for this and a further CP after the infusion. Absolute Na+ excretion (UNa + V) (,mol J. McMURRAY*, P. H. SEIDELIN & min-' ± s.e. mean) for the baseline preinfusion A. D. STRUTHERS CP, the infusion CP and post infusion recovery Department of Clinical Pharmacology, Ninewells CPwas: (a) 119 ± 15; 112 ± 14; 108 ± 14. (b) 108 Hospital and Medical School, Dundee DD1 9SY + 13; 82 + 10; 101 ± 14 (P < 0.01 vs control). Fractional Na+ excretion (FENa+) (% s.e. The renin-angiotensin-aldosterone system mean) for the equivalent CP was (a) 0.84 ± 0.1; (RAAS) is crucial in the maintenance of Na+ 0.75 ± 0.1; 0.72 ± 0.09 (b) 0.82 ± 0.09; 0.56 + balance in man. The role of aldosterone in Na+ 0.07; 0.69 ± 0.09 (P < 0.02 vs control). Fractional homeostasis is well known (Laragh, 1985). In Li+ excretion (FEL,-) (% + s.e. mean) was: (a) addition, however, there are now animal data to 31 ±2;30+2;34+3. (b)29±2;23±2;27±3. suggest that angiotensin II (All) plays a direct (P < 0.01 vs control). Distal Na+ reabsorption role, independent of aldosterone, in controlling (RDNa+) (% ± s.e. mean) was: (a) 34 ± 2; 34 + renal Na+ reabsorption.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Eosinophil Chemotaxis and Anterior Uveitis from Topical Dimoprit and Nordimoprit
    Eosinophil Chemotaxis and Anterior Uveitis From Topical Dimoprit and Nordimoprit Joel S. Mindel*tt Alan H. Friedmaat Tali Haimov,f Alex D. Kharlamb,*t and Jonathan M. Freilichj- Topical application of the H2-histamine receptor agonist, dimaprit (S-[4-N,N-dimethylaminopro- pyl]isothiourea), produced eosinophil chemotaxis into the anterior segment of rabbit eyes only when an H2-antagonist was co-administered. Nordimaprit (S-[4-N,N-dimethylaminoethyl]isothiourea), a structural homologue of dimaprit that lacked activity at histamine receptors, produced eosinophil chemotaxis whether or not an H2-antagonist was co-administered. Onset of eosinophil chemotaxis began after 2 or more days of treatment, and was accompanied by corneal edema, opacifkation, and ocular inflammation. There was no concurrent eosinophilia in the peripheral blood or in the conjunctiva. The response occurred in pigmented and albino rabbit eyes, and was facilitated by prior co-administration of proparacaine eye drops. Another dimaprit homologue without activity at histamine receptors, homodimaprit (S-[4-N,N- dimethylaminobutyl]isothiourea), did not produce eosinophil chemotaxis when applied topically, nor did the H2-agonists impromidine, histamine, or 4-methylhistamine, whether co-administered with an H2- antagonist or not. It was concluded that dimaprit and nordimaprit produced a selective eosinophil che- motaxis unrelated to H,- and H2-histamine receptor activity. However, the H2-agonist activity of dimaprit appeared to inhibit this response unless neutralized by an H2-antagonist. Topical application of dimaprit with an H2-antagonist or nordimaprit alone may allow large numbers of non-degranulated eosinophils, free of other cell types, to be harvested from the aqueous humor. Invest Ophthalmol Vis Sci 27:1504- 1511,1986 Histamine is both an Hr and H2-receptor agonist.
    [Show full text]
  • A New Specific Histamine-H2-Receptor Agonist R L Mcisaac,* B J JOHNSTON, and L P FIELDING from the Academic Surgical Unit, St
    Gut: first published as 10.1136/gut.22.7.529 on 1 July 1981. Downloaded from Gut, 1981. 22, 529-533 Gastric mucosal blood flow and acid secretory changes in man with impromidine: a new specific histamine-H2-receptor agonist R L McISAAC,* B J JOHNSTON, AND L P FIELDING From The Academic Surgical Unit, St. Mary's Hospital Medical School, London SUMMARY The effect of impromidine, a new histamine-H2-receptor agonist, on gastric mucosal blood flow (neutral red clearance) and acid secretion was studied in nine volunteers. Impromidine stimulated a dose-dependent increase in neutral red clearance and acid secretion. Simultaneous cimetidine in three doses caused a parallel shift to the right for both acid output and clearance with unchanged maxima compatible with simple surmountable antagonism. There were small cardio- vascular changes: an increased heart rate with a decreased diastolic pressure during infusion of impromidine. These changes were antagonised by cimetidine. The involvement of histamine in the control of was approved by the local ethical committee and gastric acid secretion was supported by the informed written consent was obtained from each discovery of the specific inhibitors of H2-receptors volunteer in accordance with the Declaration of on the parietal cell.' Studies in animals have also Helsinki. Gastric mucosal blood flow was shown that the gastric vasculature is sensitive to measured by the neutral red clearance technique.8 http://gut.bmj.com/ histamine through a combination of Hl- and H2- receptors although with different relative contri- GASTRIC FUNCTION TESTS AND butions.2 3In man histamine stimulates a dose- E S T I M A T I ON O F M U C O S A L B L OO1) dependent increase in both acid secretion and F L O W mucosal blood flow but the blood flow component After an overnight fast each volunteer was is relatively resistant to inhibition by cimetidine.4 intubated with a double lumen nasogastric tube A specific histamine-H,-receptor agonist would be (Sherwood 12-14 French gauge), the position on September 26, 2021 by guest.
    [Show full text]
  • Histamine, Histamine Receptors, and Their Role in Immunomodulation: an Updated Systematic Review
    The Open Immunology Journal, 2009, 2, 9-41 9 Open Access Histamine, Histamine Receptors, and their Role in Immunomodulation: An Updated Systematic Review Mohammad Shahid*,1, Trivendra Tripathi2, Farrukh Sobia1, Shagufta Moin2, Mashiatullah Siddiqui2 and Rahat Ali Khan3 1Section of Immunology and Molecular Biology, Department of Microbiology, 2Department of Biochemistry, and 3Department of Pharmacology, Faculty of Medicine, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh-202002, U.P., India Abstract: Histamine, a biological amine, is considered as a principle mediator of many pathological processes regulating several essential events in allergies and autoimmune diseases. It stimulates different biological activities through differen- tial expression of four types of histamine receptors (H1R, H2R, H3R and H4R) on secretion by effector cells (mast cells and basophils) through various immunological or non-immunological stimuli. Since H4R has been discovered very re- cently and there is paucity of comprehensive literature covering new histamine receptors, their antagonists/agonists, and role in immune regulation and immunomodulation, we tried to update the current aspects and fill the gap in existing litera- ture. This review will highlight the biological and pharmacological characterization of histamine, histamine receptors, their antagonists/agonists, and implications in immune regulation and immunomodulation. Keywords: Histamine, histamine receptors, H4-receptor, antagonists, agonists, immunomodulation. I.
    [Show full text]
  • Histamine Receptors
    HISTAMINE RECEPTORS Rob Leurs and Henk Timmerman Based on these observations histamine is Leiden/Amsterdam Centre for Drug Research considered as one of the most important Division of Medicinal Chemistry mediators of allergy and inflammation. Vrije Universiteit Amsterdam, The Netherlands Pharmacology of the Histamine Receptor Subtypes Introduction The advent of molecular biology techniques has greatly increased the number of Histamine is one of the aminergic pharmacologically distinct receptor subtypes in neurotransmitters, playing an important role in the the biogenic amine field, yet the pharmacological regulation of several (patho)physiological definition of the three distinct histamine receptor processes. In the mammalian brain histamine is subtypes by the pioneering work of Ash and synthesized in a restricted population of neurons Schild,34 Blacket al and Arrang et al 5 has still not located in the tuberomammillary nucleus of the been challenged by gene cloning approaches. posterior hypothalamus.1 These neurons project diffusely to most cerebral areas and have been Until the seventies, histamine research implicated in several brain functions (e.g. completely focused on the role of histamine in sleep/wakefulness, hormonal secretion, allergic diseases. This intensive research resulted cardiovascular control, thermoregulation, food in the development of several potent 1 intake, and memory formation). In peripheral “antihistamines” (e.g. mepyramine), which were tissues histamine is stored in mast cells, useful in inhibiting certain symptoms of allergic basophils, enterochromaffin cells and probably conditions.6 The observation that these also in some specific neurons. Mast cell histamine “antihistamines” did not antagonise all histamine- plays an important role in the pathogenesis of induced effects (e.g.
    [Show full text]
  • ( 12 ) United States Patent
    US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp .
    [Show full text]